German authorities approve Sativex


For the treatment of spasticity due to multiple sclerosis

The German health authorities have approved GW Pharmaceuticals’ Sativex (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD) oromucosal spray.

The approval has been given to the cannabis-based treatment as an add-on therapy to treat moderate to severe spasticity (muscle stiffness) due to multiple sclerosis (MS) in patients who have not responded adequately to other anti-spasticity medication.

GW Pharmaceuticals said Almirall, which holds the marketing rights to Sativex in Europe (except the UK), would launch the product in Germany in July and before the end of 2011 in Denmark and Sweden. The drug is also scheduled to be launched in Italy, Czech Republic and Austria in 2012.

Sativex, which has been developed by GW Pharmaceuticals, is also in Phase III clinical trials for the treatment of cancer pain.